Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00596791 |
Recruitment Status :
Completed
First Posted : January 17, 2008
Last Update Posted : January 12, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ocular Hypertension Open-Angle Glaucoma | Drug: tafluprost | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops |
Study Start Date : | January 2008 |
Actual Primary Completion Date : | July 2008 |
Actual Study Completion Date : | August 2008 |

Arm | Intervention/treatment |
---|---|
1 arm
Open-lable study with one arm.
|
Drug: tafluprost
prostaglandine analoque |
- Change from screening in ocular symptoms and signs [ Time Frame: at week 6 and 12 ]
- Safety and Quality of life parameters. [ Time Frame: From Screening (visit 1) to visits at week 2, 6 and 12. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00596791
Finland | |
Finn-Medi Research Oy | |
Tampere, Finland, 33520 |
Principal Investigator: | Hannu Uusitalo, Professor | Finn-Medi Research, Finland |
Responsible Party: | Auli Ropo, Study Director, Santen Oy |
ClinicalTrials.gov Identifier: | NCT00596791 |
Other Study ID Numbers: |
Santen-77552 EudraCT number 2007-004872-37 |
First Posted: | January 17, 2008 Key Record Dates |
Last Update Posted: | January 12, 2009 |
Last Verified: | January 2009 |
Glaucoma Glaucoma, Open-Angle Ocular Hypertension Eye Diseases |